Welcome to our dedicated page for INTEST SEC filings (Ticker: INTT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INTEST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INTEST's regulatory disclosures and financial reporting.
inTEST Corp ownership filing: an amendment to a Schedule 13G/A by The Vanguard Group states it beneficially owns 0 shares of inTEST Corp common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or business divisions to report holdings separately, and affirms those entities now report disaggregated beneficial ownership in reliance on SEC Release No. 34-39538.
INTEST CORP director Steven J. Abrams reported a bona fide gift of 9,000 shares of Common Stock. On March 20, 2026, he transferred these shares to a family revocable trust for no consideration. He and his spouse are co-trustees and he remains the beneficial owner of the shares held by the trust.
After the transaction, he directly holds 12,000 shares and indirectly holds 96,000 shares through the Steven J. Abrams Revocable Trust, so his overall economic exposure to INTEST CORP stock is unchanged by this gift transfer.
INTEST CORP divisional president Richard B. Rogoff reported routine equity compensation activity and an RSU vesting. On March 17, 2026, 1,010 restricted stock units converted into the same number of common shares, and 253 common shares were withheld at $14.46 per share to cover tax obligations rather than sold on the market.
On March 16, 2026, he received grants under the 2023 Stock Incentive Plan, including 2,304 common shares, a further 2,304 performance-based restricted shares that may vest in March 2029 at target performance (with up to 3,456 shares possible), and a stock option for 3,895 shares at an exercise price of $14.47 expiring on March 15, 2036.
After these transactions, Rogoff directly held 12,152 common shares. He also retained multiple stock option positions shown in the filing, including options over 13,565 shares at an exercise price of $7.74 expiring on March 17, 2035 and 9,496 shares at $11.33 expiring on March 5, 2034.
INTEST CORP division president Michael F. Goodrich reported equity compensation grants and routine tax withholding. On March 16, 2026, he received 1,843 restricted shares and 1,843 performance-based restricted shares of Common Stock, both granted at $0.00 under the 2023 Stock Incentive Plan.
The performance-based award will vest in March 2029 based on performance criteria, with a maximum of 2,765 shares vesting at top performance. He also received an Employee Stock Option for 3,116 shares at an exercise price of $14.47 per share, expiring on March 15, 2036, vesting in four equal annual installments starting March 16, 2027.
On March 17, 2026, 216 shares of Common Stock were withheld at $14.46 per share to cover tax obligations on vesting restricted stock, leaving 23,155 shares held directly after this tax-withholding disposition. He also holds additional stock options with exercise prices of $7.74 and $11.33 per share, expiring in 2035 and 2034, respectively.
INTEST CORP Division President – Electronic Test, Joseph Richard McManus Jr., reported routine equity compensation changes and related tax withholding. He received 2,535 restricted shares and 2,535 performance-based restricted shares of Common Stock that were granted under the company’s 2023 Stock Incentive Plan and vest over multiple years, including installments starting on March 16, 2027 and potential vesting in March 2029 based on performance.
He also received an employee stock option covering 4,284 shares of Common Stock at an exercise price of $14.47 per share, expiring in 2036, which vests in four equal annual installments beginning on March 16, 2027. To cover tax obligations on the vesting of restricted stock on March 17, 2026, 296 shares of Common Stock were withheld at a price of $14.46 per share. After these transactions, he directly owns 35,693 Common shares and holds several option awards with exercise prices between $7.74 and $16.06 expiring between 2031 and 2035.
inTEST Corp CFO Duncan Gilmour reported equity compensation awards, not open-market trading. He received an employee stock option for 9,736 shares of common stock at an exercise price of $14.47 per share, expiring in 2036, which will vest in four equal annual installments starting March 16, 2027.
He was also granted 5,760 time-based restricted shares that vest in four equal annual installments beginning on March 16, 2027, plus 5,760 performance-based restricted shares that may vest in March 2029 if specified performance goals are met, with a maximum of 8,640 shares eligible to vest at peak performance.
Following these awards, Gilmour holds 67,954 shares of common stock directly and 200 shares indirectly through his spouse, along with multiple previously granted stock options with exercise prices between $7.74 and $16.80 expiring from 2031 through 2035.
inTEST Corp President & CEO Richard N. Grant Jr. reported new equity awards and a small share sale. He received 13,822 restricted shares that vest in four equal annual installments starting on March 16, 2027, and 13,822 performance-based restricted shares that may vest in March 2029 depending on performance, with a maximum of 20,733 shares vesting at above-target results. He was also granted an option for 23,365 shares of common stock at an exercise price of $14.47, vesting over four years beginning on March 16, 2027.
On March 18, 2026, Grant sold 1,636 common shares at a weighted average price of $14.279 per share to satisfy tax withholding obligations tied to restricted stock vesting, under a Rule 10b5-1 trading plan adopted on December 8, 2023. After this sale, he directly owns 212,730 common shares. He also continues to hold multiple option grants with exercise prices ranging from $7.74 to $16.06 and expiration dates between 2031 and 2035.
Maginnis Gerald J. reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Gerald J. Maginnis received an award of 12,000 shares of Common Stock on March 16, 2026. The grant carried a price of $0.0000 per share, indicating a share-based award rather than a market purchase. After this transaction, he directly holds 96,057 shares.
DEWS JOSEPH W IV reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Joseph W. Dews IV received an equity award of 12,000 shares of Common Stock on March 16, 2026. The shares were granted at no cash cost per share as compensation, not bought on the open market. After this award, he directly holds 130,250 shares in total.
ABRAMS STEVEN J reported acquisition or exercise transactions in this Form 4 filing.
INTEST CORP director Steven J. Abrams received a grant of 12,000 shares of Common Stock on March 16, 2026, at no stated purchase price. After this award, he holds 21,000 shares directly. An additional 87,000 shares are held indirectly through the Steven J. Abrams Revocable Trust.